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OBJECTIVES: The metabolic syndrome is an accumulation of
risk factors and shows a high prevalence in the German popu-
lation. Treatment is limited to the treatment of single risk factors
as dyslipidemia or high blood pressure. A decision analytic
model will be developed to assess the cost-effectiveness of a new
pharmacological substance for the treatment of the metabolic
syndrome. In this context a methodological approach was devel-
oped to evaluate cost data that enables decision analyst to use
cost data for various treatment options. METHODS: Direct and
indirect costs were considered for different treatment options
and for costs of long-term complications of the metabolic syn-
drome. Field and desk research was done to obtain data con-
cerning resource utilisation and was reviewed by clinical experts.
Prices have been taken of ofﬁcial catalogues. Resource utilisation
and prices have been related in a cost database that enables to
give cost data for different treatment options and long-term com-
plications of the metabolic syndrome. RESULTS: The German
Metabolic Syndrome Cost Database includes information of
resource utilisation prices and costs. The database is constructed
in a way that it supports analysis from different perspectives.
CONCLUSIONS: A ﬂexible database was developed that
enables the adaptation of cost data for future projects due to new
developments in treatment of the metabolic syndrome.
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DEVELOPMENT AND VALIDATION OF A CLAIMS-BASED RISK
ASSESSMENT MODEL TO PREDICT PHARMACY
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OBJECTIVES: To empirically develop and validate the Medic-
aid RxCost Model, a prospective risk assessment model, that
uses claims-based diagnostic information to predict future phar-
macy expenditures. The Medicaid Mixed RxCost (MRxCost)
Model was developed to explore the gain in predictive power
associated with adding drug information. METHODS: A retro-
spective longitudinal cohort study using a California Medicaid
sample from 1998 through 2000 was undertaken. Persons who
were continuously enrolled for at least 13 months, who were 18
to 64 years of age, not eligible for Medicare and were not admit-
ted for a hospital or nursing home stay >30 days were selected.
A training sample consisting of 138,454 persons was utilized to
develop the models using OLS regression. A random holdout
sample of 92,621 was utilized to validate the models and to
compare the performance of each model. The discrimination of
the models was also compared to a demographic model and the
Chronic Illness and Disability Payment System (CDPS) model.
Prediction ratios and measures of discrimination were estimated
for hypothetical physician groups with varying patient sizes.
RESULTS: Subjects were on average 35 years old, 72% were
female, and annualized prescription expenditures were $497.
Out of a total of 101 variables explored for the Rx-Cost model,
56 were retained after variable selection procedures and clinical
review. The R-square value for the Medicaid RxCost Model, the
Medicaid MRxCost Model and the CDPS model using the vali-
dation sample was 0.24, 0.30 and 0.04 respectively. The predic-
tion ratio = 0.90 and r-square = 0.50 were highest for large hypo-
thetical physician groups (500 patients), but acceptable measures
were observed for groups as low as 10 members. CONCLU-
SIONS: The Medicaid RxCost Model was successfully developed
and it substantially outperformed the CDPS model in terms of
R-square. The Medicaid MRxCost Model proved that supple-
menting drug information can improve discriminatory power.
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OBJECTIVES: In 2002 in Montenegro there was no efﬁcient
system which should follow up the prescribing practice in out-
patient clinics. The total expenses for drugs were so high that
they threatened to diminish the whole system of drug supply.
METHODS: Therefore in 2003 at the whole Montenegro
Republic a system to follow up the drug prescribing in outpa-
tient practice was implemented. System consisted from the
central unit in Republic health department, and units in the all
pharmacies which give drugs on the prescriptions covered ﬁnan-
cially by Republic health department. System started on
01.01.2004. System contains bases with all drugs on market in
Montenegro, all doctors, pharmacists, drug users and enables to
follow the drugs way from each doctor through pharmay to the
patient. RESULTS: At the same time Republic health department
introduced the new list of drugs refunded by Republic health
department. The list of drugs refunded by Republic health
department, so called Positive list, covered all important drugs,
and was prepared in accordance to new pharmacotherapeutic
guidelines. ATC/DDD methodology of drugs was used. Analysis
performed one year after implementation showed that the use of
drugs signiﬁcantly (1568%) decreased when compared with
2002 year. Expenses were 1.5mil E lower that on 2002/2003.
From the all drugs, the most often issued drugs were for arter-
ial hypertension and for tonsilopharingitis, more than 25% of
all prescriptions. The structure of drugs prescribed was improved
when compared with pre implementation period. CONCLU-
SIONS: Permanent monitoring and periodic analyses of infor-
mations obtained from information system in the future will
additionally improve rationalization of the drug prescribing.
Monitoring and analyses will show if some other administrative
measurements are needed to keep this positive trend on.
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OBJECTIVE: Malnutrition during hospital stay has been con-
sistently reported since the 1970s. In addition to the clinical
implications malnutrition may have, it also leads to increased
length of stay and drug usage due to complications. We report
from a large observational database of 26 Belgian hospitals to
document the potential economic impact of hospital malnutri-
tion. METHODS: As a legal requirement, Belgian hospitals must
register case-mix data for each inpatient stay in a minimum basic
data set (MBDS). We extracted exhaustive and anonymous stay
data from 26 hospitals (2nd semester, 2003) and identiﬁed mal-
nourished patients as patients for whom ICD9-CM codes for
“underweight” (783.22) or “severe weight loss” (783.21) were
recorded. A matched analysis on APR-DRG, age and gender was
then performed to compare inpatient pharmaceuticals costs, pro-
